These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34273398)

  • 21. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
    Van den Eynden J; Umapathy G; Ashouri A; Cervantes-Madrid D; Szydzik J; Ruuth K; Koster J; Larsson E; Guan J; Palmer RH; Hallberg B
    Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
    Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
    FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells.
    Schönherr C; Yang HL; Vigny M; Palmer RH; Hallberg B
    Oncogene; 2010 May; 29(19):2817-30. PubMed ID: 20190816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
    Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
    Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lysophosphatidic Acid Stimulates Mitogenic Activity and Signaling in Human Neuroblastoma Cells through a Crosstalk with Anaplastic Lymphoma Kinase.
    Dedoni S; Olianas MC; Onali P
    Biomolecules; 2024 May; 14(6):. PubMed ID: 38927035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides.
    Ota Y; Yoda H; Inoue T; Watanabe T; Shinozaki Y; Takatori A; Nagase H
    PLoS One; 2021; 16(9):e0257718. PubMed ID: 34591871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.
    Di Paolo D; Ambrogio C; Pastorino F; Brignole C; Martinengo C; Carosio R; Loi M; Pagnan G; Emionite L; Cilli M; Ribatti D; Allen TM; Chiarle R; Ponzoni M; Perri P
    Mol Ther; 2011 Dec; 19(12):2201-12. PubMed ID: 21829174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
    Cai J; Jacob S; Kurupi R; Dalton KM; Coon C; Greninger P; Egan RK; Stein GT; Murchie E; McClanaghan J; Adachi Y; Hirade K; Dozmorov M; Glod J; Boikos SA; Ebi H; Hao H; Caponigro G; Benes CH; Faber AC
    Cell Rep; 2022 Jul; 40(4):111095. PubMed ID: 35905710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
    Pacenta HL; Macy ME
    Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
    Yi B; Yang J; Wang L
    Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
    Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R
    J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition.
    Borenäs M; Umapathy G; Lind DE; Lai WY; Guan J; Johansson J; Jennische E; Schmidt A; Kurhe Y; Gabre JL; Aniszewska A; Strömberg A; Bemark M; Hall MN; Eynden JVD; Hallberg B; Palmer RH
    Proc Natl Acad Sci U S A; 2024 Jan; 121(1):e2315242121. PubMed ID: 38154064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time-resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling.
    Vemulapalli V; Chylek LA; Erickson A; Pfeiffer A; Gabriel KH; LaRochelle J; Subramanian K; Cao R; Stegmaier K; Mohseni M; LaMarche MJ; Acker MG; Sorger PK; Gygi SP; Blacklow SC
    Elife; 2021 Mar; 10():. PubMed ID: 33755016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
    Guan J; Fransson S; Siaw JT; Treis D; Van den Eynden J; Chand D; Umapathy G; Ruuth K; Svenberg P; Wessman S; Shamikh A; Jacobsson H; Gordon L; Stenman J; Svensson PJ; Hansson M; Larsson E; Martinsson T; Palmer RH; Kogner P; Hallberg B
    Cold Spring Harb Mol Case Stud; 2018 Aug; 4(4):. PubMed ID: 29907598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.
    Fransson S; Hansson M; Ruuth K; Djos A; Berbegall A; Javanmardi N; Abrahamsson J; Palmer RH; Noguera R; Hallberg B; Kogner P; Martinsson T
    Genes Chromosomes Cancer; 2015 Feb; 54(2):99-109. PubMed ID: 25251827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.
    Bachetti T; Di Paolo D; Di Lascio S; Mirisola V; Brignole C; Bellotti M; Caffa I; Ferraris C; Fiore M; Fornasari D; Chiarle R; Borghini S; Pfeffer U; Ponzoni M; Ceccherini I; Perri P
    PLoS One; 2010 Oct; 5(10):. PubMed ID: 20957039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ATR inhibition enables complete tumour regression in ALK-driven NB mouse models.
    Szydzik J; Lind DE; Arefin B; Kurhe Y; Umapathy G; Siaw JT; Claeys A; Gabre JL; Van den Eynden J; Hallberg B; Palmer RH
    Nat Commun; 2021 Nov; 12(1):6813. PubMed ID: 34819497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration.
    Huang H; Gont A; Kee L; Dries R; Pfeifer K; Sharma B; Debruyne DN; Harlow M; Sengupta S; Guan J; Yeung CM; Wang W; Hallberg B; Palmer RH; Irwin MS; George RE
    Cell Rep; 2021 Jul; 36(2):109363. PubMed ID: 34260934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome.
    Chong Y; Liu Y; Lu S; Cai B; Qin H; Chang CS; Ren M; Cowell JK; Hu T
    Int J Cancer; 2020 Apr; 146(8):2243-2254. PubMed ID: 31525277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.